Cells and methodology to generate non-segmented negative-strand rna viruses
AssigneeInstitut Pasteur
InventorsFrédéric Tangy, Pierre Charneau, Yves Jacob
Life of this patent
Estimating the term…
Loading patent…
AssigneeInstitut Pasteur
InventorsFrédéric Tangy, Pierre Charneau, Yves Jacob
Estimating the term…
The present invention relates to recombinant cells as well as to methods for the generation of non-segmented negative-sense single-stranded RNA viruses (NNV or mononegavirales) from cloned deoxyribonucleic acid (cDNA), especially from measles virus and in particular from attenuated strains such as those approved for vaccination, in particular from the attenuated Schwarz measles virus and various recombinant Schwarz measles-based viruses expressing heterologous sequences. Such rescued viruses can be used, after amplification, as vaccines for immunization against measles and/or against the heterologous peptides or proteins expressed.
A cell stably producing at least a RNA polymerase, a nucleoprotein (N) of a non-segmented negative-strand RNA virus and a phosphoprotein (P) of a non-segmented negative-strand RNA virus, or functional derivatives thereof.
A cell obtainable by recombination of its genome with:
A cell obtainable by recombination of its genome with an expression vector comprising:
An expression retroviral-derived vector, in particular a plasmid, comprising a DNA flap and at least one nucleic acid encoding a protein necessary for the rescue of a non-segmented negative-strand RNA virus.
An expression vector comprising a nucleic acid encoding a L protein of a non-segmented negative-strand RNA virus, which is the plasmid pEMC-LSchw deposited with the CNCM on December 18, 2007, under number 1-3881.
Method to produce infectious, recombinant, non-segmented negative-strand RNA virus comprising or consisting of:
Method to produce infectious, recombinant, non-segmented negative-strand RNA virus comprising or consisting of:
Dependencies are inferred from the claim text.